Showing 2681-2690 of 4166 results for "".
- Leo Lens Pharma Lead Asset Ready for Human Clinical Evaluationhttps://modernod.com/news/leo-lens-pharma-lead-asset-ready-for-human-clinical-evaluation/2477927/Leo Lens Pharma has announced that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for 1 week. After a pre-IND meeting with the FDA, Leo Lens has now
- Aldeyra Therapeutics Advances Investigational HSP90 Inhibitor to Clinical Testing for COVID-19https://modernod.com/news/aldeyra-therapeutics-advances-ivestigational-hsp90-inhibitor-to-clinical-testing-for-covid-19/2477799/Aldeyra Therapeutics, which has several drug candidates for the treatment of ocular inflammatory diseases, announced the planned advancement of the investigational new HSP90 inhibitor ADX-1612 to clinical testing for COVID-19, and provided an update on ADX-629, a novel investigational RASP inhibi
- New COVID-19 Clinical Trial Supported by Octapharma USAhttps://modernod.com/news/new-covid-19-clinical-trial-supported-by-octapharma-usa/2477593/Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, MD, of Sharp Memorial Hospital in San Diego, focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure who become ventilator depen
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval-2/2477164/Staar Surgical announced that the FDA, in a letter dated December 6, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ VISIAN Implantable Collamer Lens for Myopia, and EVO/EVO+ VISIAN To
- ReNeuron Presents Positive Clinical Data at the American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/reneuron-presents-positive-clinical-data-at-the-american-academy-of-ophthalmology-annual-meeting/2477009/ReNeuron Group has announced that positive efficacy data were presented during the weekend at the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco from the company’s phase 1/2a clinical trial of its hRPC stem cell therapy in retinitis
- Bausch + Lomb Announces New Scientific and Clinical Analyses to be Presented at AAOhttps://modernod.com/news/bausch-lomb-announces-new-scientific-and-clinical-analyses-to-be-presented-at-aao/2476944/Bausch + Lomb announced that eight new scientific poster and clinical presentations involving the company’s products, as well as data from the company’s Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meeting of the America
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval/2476825/Staar Surgical announced that the FDA, in a letter dated August 23, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ Visian Implantable Collamer Lens for myopia, and EVO/EVO+ Visian Tor
- Nicox Announces Completes Enrollment in NCX 470 Phase 2 Clinical Studyhttps://modernod.com/news/nicox-announces-completion-of-enrollment-in-ncx-470-phase-2-clinical-study-with-topline-results-on-track-for-early-4q-2019/2476734/Nicox SA announced that it has completed enrollment of patients in its multicenter, phase 2 clinical study evaluating NCX 470 nitric oxide (NO)-donating bimatoprost analog being tested in patients with open-angle glaucoma or ocular hypertension for its ability to lower IOP. This study is a head-t
- Alcon to Showcase New Clinical Data, Innovative Technology at ASCRShttps://modernod.com/news/alcon-to-showcase-new-clinical-data-innovative-technology-at-ascrs/2476542/Alcon will feature new clinical data along with innovative product designs and technology for the Cataract Refractive Suite during the American Society of Cataract and Refractive Surgery (ASCRS) 2019 annual meeting, taking place May 3-7 in San Diego. The company, which recently became an independ
- Department of Defense Grant for Clinical Trial of Stem Cell Therapy for Eye Injurieshttps://modernod.com/news/department-of-defense-grant-for-clinical-trial-of-stem-cell-therapy-for-eye-injuries/2479809/Researchers at the University of Illinois at Chicago have received a 4-year, $5.25 million grant from the U.S. Department of Defense to lead a multisite clinical trial to test the efficacy of a stem cell-based treatment for eye injuries. The treatment uses mesenchymal stem cells—cells that